|
 |
| |
| Home > Company |
| |
|
| |
| Tissue Regeneration Therapeutics Inc. (TRT), developing stem cells for therapeutic applications in regenerative medicine… |
| |
| Founded in February of 2004, TRT is committed to uncompromised protection of human life by providing stem cell therapy solutions that are generated from umbilical cord tissue, thereby providing an alternative to embryonic stem cells. |
| |
| TRT is a Canadian Controlled Private Corporation (CCPC) life sciences company founded on the research and intellectual property of Dr. John E. Davies and his research team at the Institute for Biomaterials and Biomedical Engineering, University of Toronto (U of T). |
| |
|
| |
| Stem Cell Therapy: Clinical development of HUCPVC Therapy™, a source of non-embryonic stem cells for patient care |
| |
| Stem Cell Banking: HUCPVC Storage™ for the long-term storage of patient Umbilical Cord Tissue stem cells collected after the full term birth of your child |
| |
| Bone Augmentation: Assisting the natural renewal and remodeling of fractured and broken bones with OsteoScaf™, our macroporous biodegradable scaffold |
|
|
 |
|
| |
| |
Founded February 2004
Canadian Controlled Private Corporation (CCPC) life sciences company |
| |
| Management: Dr. John E.
Davies, President; Dr. Jeffrey D. Turner, Chief Executive
Officer; and Mr. Dana Rath, Chief Financial Officer |
| |
| |
|
|
|
